Bioresorbable Scaffolds Market Size

Bioresorbable Scaffolds Market size is expected to be propelled notably over 2024 to 2032, driven by the alarming rise in incidences of cardiovascular diseases worldwide. According to WHO, annually, cardiovascular diseases (CVDs) claim around 17.9 million lives worldwide, making them the leading cause of death globally. As these conditions require interventions like angioplasty and stent placement, there's a growing demand for innovative, bioresorbable scaffolds that can provide temporary support to the blood vessel and gradually dissolve over time, promoting natural vessel healing.

Rising strategic initiatives undertaken by industry players to develop bioresorbable scaffolds will increase its adoption in the coming years. Companies are emphasizing on R&D projects and collaborations to develop scaffolds that can be completely absorbed and naturally restore movement of artery. For instance, in 2023, Evonik announced collaboration with BellaSeno to commercialize 3D-printed scaffolds for bone regeneration. The scaffolds are developed with Evonik’s Resomer polymers and are used for complex and large bone defects.

Bioresorbable Scaffolds Market Trends

Regulatory agencies, across the globe play a crucial role in driving market growth by providing approvals and clearances for bioresorbable scaffolds. With the regulatory landscape becoming more favorable towards innovative medical devices, companies are encouraged to invest in R&D, leading to the commercialization of new bioresorbable scaffold products.

Bioresorbable Scaffolds Market Analysis

Drug eluting coronary scaffolds segment is slated to amass considerable gains through 2023, driven by their usage in setting of primary angioplasty. These devices boast of benefits such as reduced risk of infections and biodegradable property that enhances surgical outcomes. Additionally, drug eluting coronary scaffolds limit incidences of stent thrombosis and restenosis to restore vascular physiology. These characteristics enhance patient outcome.

The hospital end-use segment is anticipated to record decent revenue till 2032, attributed to the growing chronic disease burden globally. With advanced medical facilities as well as experienced professionals, hospitals are preferred among the patients with heart conditions. Furthermore, initiatives taken by public hospitals to offer quality and cost-effective treatment make it easier for patients to afford bioresorbable scaffolds.  

North America bioresorbable scaffolds market is estimated to generate decent revenue till 2032, owing to the demographic trends of the region such as growing baby boomers susceptible to numerous chronic conditions, rising disease burden, and changing lifestyle of people. Additionally, strong foothold of industry players in the region will provide innovative solutions that will increase adoption rate of bioresorbable scaffolds and bolster returns.

Bioresorbable Scaffolds Market Share

Notable players operating in the bioresorbable scaffolds industry are:

• Abbott
• Medtronic
• Boston Scientific Corporation
• Biotronik
• REVA Medical
• Elixir Medical Corporation
• Amaranth Medical
• Kyoto Medical Planning
• B. Braun
• Cardinal Health
• Lombard Medical
• Xenogenics Corporation
• Translumina
• MicroPort Scientific Corporation and TERUMO CORPORATION
  

Bioresorbable Scaffolds Industry News

• In Mach 2023, NVIDIA and Medtronic teamed up to accelerate AI development in healthcare and deploy AI-driven solutions for patient care. Their collaboration will integrate NVIDIA's healthcare and edge AI technologies into Medtronic's GI Genius™ intelligent endoscopy module, the first FDA-cleared AI-assisted colonoscopy tool for detecting polyps linked to colorectal cancer.